Journal of Pharmacy Practice and ResearchVolume 41, Issue 1 p. 14-16 EditorialFree Access Beyond CYP2C19 – A New Chapter in Clopidogrel Pharmacogenomics Dr Thomas M Polasek BSc, BPharm (Hons), PhD, MSHP, Dr Thomas M Polasek BSc, BPharm (Hons), PhD, MSHP Lecturer in Clinical Pharmacology [email protected] Department of Clinical Pharmacology, Flinders University and Flinders Medical Centre, Adelaide, SA, 5042Search for more papers by this author Dr Thomas M Polasek BSc, BPharm (Hons), PhD, MSHP, Dr Thomas M Polasek BSc, BPharm (Hons), PhD, MSHP Lecturer in Clinical Pharmacology [email protected] Department of Clinical Pharmacology, Flinders University and Flinders Medical Centre, Adelaide, SA, 5042Search for more papers by this author First published: 13 April 2015 https://doi.org/10.1002/j.2055-2335.2011.tb00054.xCitations: 2AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Winslow R. Plavix rival gains from studies. Wall St 30 August 2010. 2Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010; 103: 841– 8. 3Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O, et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 2009; 37: 2145– 52. 4Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92– 9. 5Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA 2010; 304: 1821– 30. 6Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110– 16. Citing Literature Volume41, Issue1March 2011Pages 14-16 ReferencesRelatedInformation